Trial Profile
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2017
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary) ; Indacaterol
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Registrational
- Acronyms EXPEDITION; FLIGHT-3
- Sponsors Novartis
- 24 May 2017 Results assessing improvement in lung function with indacaterol/glycopyrrolate twice daily versus indacaterol once daily in patients with moderate-to-severe COPD, presented at the 113th International Conference of the American Thoracic Society
- 24 May 2017 Results from analysis of FLIGHT trials (FLIGHT1, FLIGHT2 and FLIGHT3 studies) presented at the 113th International Conference of the American Thoracic Society
- 23 May 2017 According to a Sunovion Pharmaceuticals media release, data from this study was presented at the 2017 American Thoracic Society International Conference (ATS 2017).